Print

Featured Studies Results

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101 /a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Understanding the Needs of LGBTQIA+ Caregivers Supporting People with Cancer

https://www.facingourrisk.org/research-clinical-trials/study/346 /understanding-the-needs-of-lgbtqia-caregivers-supporting-people-with-cancer

Surveys, Registries, Interviews
Survey and interview for LGBTQIA+ caregivers supporting people with cancer

HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/342 /heal-abc-study-harnessing-e-mindfulness-approaches-for-living-after-breast-cancer

Clinicaltrials.gov identifier:
NCT06748222 (https://clinicaltrials.gov/show/NCT06748222)

Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression

Clinical and Molecular Studies of Li-Fraumeni Syndrome and TP53-Associated Disorders

https://www.facingourrisk.org/research-clinical-trials/study/340 /clinical-and-molecular-studies-of-li-fraumeni-syndrome-and-tp53-associated-disorders

Clinicaltrials.gov identifier:
NCT04367246 (https://clinicaltrials.gov/show/NCT04367246)

Surveys, Registries, Interviews
This study will enroll Li-Fraumeni Syndrome patients, family members, and household members. Patients and family/household members may be enrolled with informed consent

Using the Drug eRapa to Prevent the Growth of Polyps in People with Familial Adenomatous Polyposis (SERENTA)

https://www.facingourrisk.org/research-clinical-trials/study/348 /study-of-the-drug-erapa-in-people-with-familial-adenomatous-polyposis-serenta

Clinicaltrials.gov identifier:
NCT06950385 (https://clinicaltrials.gov/show/NCT06950385)

Prevention
Prevention study for people with Familial Adenomatous Polyposis (FAP) who have polyps in the colon or rectum

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug, Axatilimab, Combined with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/345 /treating-her2-negative-brca12-or-palb2-positive-metastatic-breast-cancer-using-a-new-drug-combined-with-olaparib

Clinicaltrials.gov identifier:
NCT06488378 (https://clinicaltrials.gov/show/NCT06488378)

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)

Treatment
Biomarker study for people with early-stage breast cancer

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

https://www.facingourrisk.org/research-clinical-trials/study/149 /promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness

Clinicaltrials.gov identifier:
NCT04995198 (https://clinicaltrials.gov/show/NCT04995198)

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

Testing a Shorter Course of Chemo- and Immunotherapy (Without Anthracycline Drugs) for People With Early-Stage Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/343 /a-study-testing-shorter-safer-chemo-immunotherapy-without-anthracycline-drugs-for-people-with-early-stage-triple-negative-breast-cancer

Clinicaltrials.gov identifier:
NCT05929768 (https://clinicaltrials.gov/show/NCT05929768)

Treatment
Treatment study for early-stage triple-negative breast cancer

What Happens to Tissue or Blood Samples you Donate as Part of Research?

https://www.facingourrisk.org/research-clinical-trials/study/327 /what-happens-to-tissue-or-blood-samples-you-donate-as-part-of-research

Surveys, Registries, Interviews
Survey to share your views on a new method to track research specimens

Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222 /pancreatic-cancer-screening-studycaps5

Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)

Prevention
Screening study for people at high risk for pancreatic cancer

Registry for People at Increased Risk for Pancreatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/331 /registry-for-people-at-increased-risk-for-pancreatic-cancer

Clinicaltrials.gov identifier:
NCT06151223 (https://clinicaltrials.gov/show/NCT06151223)

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334 /study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288 /testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

The American Cancer Society’s “VOICES of Black Women” Observational Study

https://www.facingourrisk.org/research-clinical-trials/study/336 /the-american-cancer-societys-voices-of-black-women-observational-study

Surveys, Registries, Interviews
Survey for Black women who have never been diagnosed with cancer

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304 /olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

https://www.facingourrisk.org/research-clinical-trials/study/339 /studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1

Clinicaltrials.gov identifier:
NCT06120491 (https://clinicaltrials.gov/show/NCT06120491)

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/332 /understanding-risk-factors-for-stomach-cancer-in-people-with-inherited-mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.